FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or <i>RAS</i>/<i>BRAFV600E-</i>mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group.
Cornelis J.A. Punt(University of Amsterdam), Rutger‐Jan Swijnenburg(Amsterdam University Medical Centers), Marinde J. G. Bond(Utrecht University), Cornelis Verhoef(Erasmus MC Cancer Institute), Helgi H. Helgason(Medisch Centrum Haaglanden), Emile D. Kerver(OLVG), Mathijs P. Hendriks(Northwest Hospital), Mike S.L. Liem(Medisch Spectrum Twente), Jan Willem de Groot(Isala), Geert Kazemier(Amsterdam Neuroscience), Joost M. Klaase(University Medical Center Groningen), Karen Bolhuis(The Netherlands Cancer Institute), Aysun Komurcu(Netherlands Comprehensive Cancer Organisation), Arjen M. Rijken(Amphia Ziekenhuis), Johannes H.W. de Wilt(Radboud University Nijmegen), Martinus J. van Amerongen(Sint Maartenskliniek), Marc Engelbrecht(University of Amsterdam), Marta López‐Yurda(The Netherlands Cancer Institute), O. J. L. Loosveld(Amphia Ziekenhuis), Koert P. de Jong(University of Padua)
Cited by 14
Related Papers
Direct detection of early-stage cancers using circulating tumor DNA
|Science Translational Medicine|2017|1.1k
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2010|1k
From tumour heterogeneity to advances in precision treatment of colorectal cancer
|Nature Reviews Clinical Oncology|2016|692
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
|The Lancet|2008|642
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma
|Transplantation|2015|417